Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine

Vaccine

Volumn 26, Issue 49, 2008, Pages 6225-6231

  Lang, Krystle A ^a   Yan, Jian ^a   Draghia Akli, Ruxandra ^b   Khan, Amir ^b   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VGX Pharmaceuticals Inc   (United States)

Author keywords

Consensus; DNA vaccine; HCV; NS3; NS4A

Indexed keywords

DNA VACCINE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRUG EFFECT; DRUG SPECIFICITY; FEMALE; GENOTYPE; HEPATITIS C VIRUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RHESUS MONKEY;

AMINO ACID SEQUENCE; ANIMALS; CARRIER PROTEINS; CELL SEPARATION; ELECTROPORATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FLUORESCENT ANTIBODY TECHNIQUE; GENOTYPE; HEPACIVIRUS; IMMUNITY, CELLULAR; IMMUNIZATION; INTERFERON-GAMMA; MACACA MULATTA; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; SPLEEN; VACCINES, DNA; VIRAL NONSTRUCTURAL PROTEINS; VIRAL PROTEINS;

EID: 55249115746     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.052     Document Type: Article

References (40)

1. Thomson B.J., and Finch R.G. Hepatitis C virus infection. Clin Microbiol Infect 11 2 (2005) 86-94
2. Bowen D.G., and Walker C.M. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436 7053 (2005) 946-952
3. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25 27 (2006) 3834-3847
4. Salomon J.A., et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 290 2 (2003) 228-237
5. Manns M.P., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 9286 (2001) 958-965
6. Weiner A.J., et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol 75 15 (2001) 7142-7148
7. Bassett S.E., et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33 6 (2001) 1479-1487
8. Lanford R.E., et al. Cross-genotype immunity to hepatitis C virus. J Virol 78 3 (2004) 1575-1581
9. Houghton M., and Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 436 7053 (2005) 961-966
10. Pawlotsky J.M. Diagnostic tests for hepatitis C. J Hepatol 31 Suppl 1 (1999) 71-79
11. Farci P., et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 258 5079 (1992) 135-140
12. Lai M.E., et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 343 8894 (1994) 388-390
13. Cooper S., et al. Analysis of a successful immune response against hepatitis C virus. Immunity 10 4 (1999) 439-449
14. Post J.J., et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 189 10 (2004) 1846-1855
15. Lechner F., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191 9 (2000) 1499-1512
16. Gerlach J.T., et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117 4 (1999) 933-941
17. Thimme R., et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194 10 (2001) 1395-1406
18. Grakoui A., et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302 5645 (2003) 659-662
19. Missale G., et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98 3 (1996) 706-714
20. Diepolder H.M., et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346 8981 (1995) 1006-1007
21. Martin T., et al. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther 10 5 (1999) 759-768
22. Nichols W.W., et al. Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci 772 (1995) 30-39
23. Chattergoon M., Boyer J., and Weiner D.B. Genetic immunization: a new era in vaccines and immune therapeutics. FASEB J 11 10 (1997) 753-763
24. Liu M.A., and Ulmer J.B. Human clinical trials of plasmid DNA vaccines. Adv Genet 55 (2005) 25-40
25. Andre S., et al. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72 2 (1998) 1497-1503
26. Deml L., et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol 75 22 (2001) 10991-11001
27. Laddy D.J., et al. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 25 16 (2007) 2984-2989
28. Frelin L., et al. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Ther 11 6 (2004) 522-533
29. Hirao L.A., et al. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 26 3 (2008) 440-448
30. Luckay A., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 81 10 (2007) 5257-5269
31. Ahlen G., et al. In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 179 7 (2007) 4741-4753
32. Yan J., et al. Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther 15 2 (2007) 411-421
33. Rolland M., et al. Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins. J Virol 81 16 (2007) 8507-8514
34. Boyer J.D., et al. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J Med Primatol 34 5-6 (2005) 262-270
35. Frelin L., et al. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Gene Ther 10 8 (2003) 686-699
36. Wolk B., et al. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol 74 5 (2000) 2293-2304
37. Tanji Y., et al. Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. J Virol 69 3 (1995) 1575-1581
38. Rehermann B., et al. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 98 6 (1996) 1432-1440
39. Nelson D.R., et al. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 158 3 (1997) 1473-1481
40. Capone S., et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J Immunol 177 10 (2006) 7462-7471